COMPASS PATHWAYS PLC Net Income
COMPASS PATHWAYS PLC (CMPS) reported Net Income of -$253.79 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2026-08-05
- COMPASS PATHWAYS PLC net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$253.79M.
- COMPASS PATHWAYS PLC net income (loss) attributable to parent for the quarter ending 2026-03-31 was $91.20M.
- COMPASS PATHWAYS PLC net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$75.78M.
- COMPASS PATHWAYS PLC net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$137.72M.
- COMPASS PATHWAYS PLC net income (loss) attributable to parent for fiscal 2022 was -$91.50M.
- COMPASS PATHWAYS PLC net income (loss) attributable to parent for fiscal 2021 was -$71.74M.
- COMPASS PATHWAYS PLC net income (loss) attributable to parent for fiscal 2020 was -$60.33M.
- COMPASS PATHWAYS PLC net income (loss) attributable to parent for fiscal 2019 was -$19.61M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 3 month as first filed | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month | Net Income (Loss) Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$253.79M 10-Q · filed 2026-08-05 | -$162.59M 10-Q · filed 2026-08-05 | -$238.38M derived: sum of 3 quarters · filed 2026-08-05 | -$376.09M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2026-03-31 | $91.20M 10-Q · filed 2026-08-05 | $15.42M derived: sum of 2 quarters · filed 2026-08-05 | -$122.30M derived: sum of 3 quarters · filed 2026-08-05 | -$160.70M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-12-31 | -$75.78M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-15 | -$213.50M derived: sum of 2 quarters · filed 2026-04-15 | -$251.90M derived: sum of 3 quarters · filed 2026-08-05 | -$269.77M DEF 14A · filed 2026-04-15 | -$287.86M 10-K · filed 2026-03-24 | |
| 2025-09-30 | -$137.72M 10-Q · filed 2025-11-04 | -$176.12M derived: sum of 2 quarters · filed 2026-08-05 | -$193.98M 10-Q · filed 2025-11-04 | -$237.32M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-06-30 | -$38.40M 10-Q · filed 2026-08-05 | -$56.27M 10-Q · filed 2026-08-05 | -$99.60M derived: sum of 3 quarters · filed 2026-08-05 | -$138.10M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-03-31 | -$17.86M 10-Q · filed 2026-08-05 | -$61.20M derived: sum of 2 quarters · filed 2026-08-05 | -$99.70M derived: sum of 3 quarters · filed 2026-08-05 | -$137.80M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2024-12-31 | -$43.33M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-15 | -$81.83M derived: sum of 2 quarters · filed 2026-04-15 | -$119.94M derived: sum of 3 quarters · filed 2026-04-15 | -$155.12M DEF 14A · filed 2026-04-15 | ||
| 2024-09-30 | -$38.50M 10-Q · filed 2025-11-04 | -$76.60M derived: sum of 2 quarters · filed 2025-11-04 | -$111.79M 10-Q · filed 2025-11-04 | -$144.32M derived: sum of 4 quarters · filed 2026-04-15 | ||
| 2024-06-30 | -$38.10M 10-Q · filed 2025-11-04 | -$73.29M 10-Q · filed 2025-07-31 | -$105.82M derived: sum of 3 quarters · filed 2026-04-15 | -$139.21M derived: sum of 4 quarters · filed 2026-04-15 | ||
| 2024-03-31 | -$35.19M 10-Q · filed 2025-11-04 | -$67.72M derived: sum of 2 quarters · filed 2026-04-15 | -$101.11M derived: sum of 3 quarters · filed 2026-04-15 | -$129.44M derived: sum of 4 quarters · filed 2026-04-15 | ||
| 2023-12-31 | -$32.53M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-15 | -$65.92M derived: sum of 2 quarters · filed 2026-04-15 | -$94.26M derived: sum of 3 quarters · filed 2026-04-15 | -$118.46M DEF 14A · filed 2026-04-15 | ||
| 2023-09-30 | -$33.39M 10-Q · filed 2024-10-31 | -$61.72M derived: sum of 2 quarters · filed 2024-10-31 | -$85.93M 10-Q · filed 2024-10-31 | -$116.86M derived: sum of 4 quarters · filed 2024-10-31 | ||
| 2023-06-30 | -$28.34M 10-Q · filed 2024-10-31 | -$52.54M 10-Q · filed 2024-08-01 | -$83.47M derived: sum of 3 quarters · filed 2024-10-31 | -$101.84M derived: sum of 4 quarters · filed 2024-10-31 | ||
| 2023-03-31 | -$24.21M 10-Q · filed 2024-10-31 | -$55.13M derived: sum of 2 quarters · filed 2024-10-31 | -$73.50M derived: sum of 3 quarters · filed 2024-10-31 | -$94.54M derived: sum of 4 quarters · filed 2024-10-31 | ||
| 2022-12-31 | -$30.93M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$49.30M derived: sum of 2 quarters · filed 2024-02-29 | -$70.33M derived: sum of 3 quarters · filed 2024-02-29 | -$91.50M 10-K · filed 2024-02-29 | ||
| 2022-09-30 | -$18.37M 10-Q · filed 2023-11-02 | -$39.41M derived: sum of 2 quarters · filed 2023-11-02 | -$60.58M 10-Q · filed 2023-11-02 | -$86.23M derived: sum of 4 quarters · filed 2024-02-29 | ||
| 2022-06-30 | -$21.04M 10-Q · filed 2023-11-02 | -$42.21M 10-Q · filed 2023-08-03 | -$67.86M derived: sum of 3 quarters · filed 2024-02-29 | -$83.71M derived: sum of 4 quarters · filed 2024-02-29 | ||
| 2022-03-31 | -$21.17M 10-Q · filed 2023-11-02 | -$46.82M derived: sum of 2 quarters · filed 2024-02-29 | -$62.67M derived: sum of 3 quarters · filed 2024-02-29 | -$80.20M derived: sum of 4 quarters · filed 2024-02-29 | ||
| 2021-12-31 | -$25.65M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$41.50M derived: sum of 2 quarters · filed 2024-02-29 | -$59.03M derived: sum of 3 quarters · filed 2024-02-29 | -$71.74M 10-K · filed 2024-02-29 | ||
| 2021-09-30 | -$15.85M 10-Q · filed 2022-11-03 | -$33.38M derived: sum of 2 quarters · filed 2022-11-03 | -$46.09M 10-Q · filed 2022-11-03 | -$64.90M derived: sum of 4 quarters · filed 2023-02-28 | ||
| 2021-06-30 | -$17.53M 10-Q · filed 2022-11-03 | -$30.24M 10-Q · filed 2022-08-04 | -$49.05M derived: sum of 3 quarters · filed 2023-02-28 | -$64.90M derived: sum of 4 quarters · filed 2023-02-28 | ||
| 2021-03-31 | -$12.71M 10-Q · filed 2022-11-03 | -$31.52M derived: sum of 2 quarters · filed 2023-02-28 | -$47.37M derived: sum of 3 quarters · filed 2023-02-28 | -$64.90M derived: sum of 4 quarters · filed 2023-02-28 | ||
| 2020-12-31 | -$18.81M derived: 10-K 12 month − 6-K 9 month · filed 2023-02-28 | -$34.66M derived: sum of 2 quarters · filed 2023-02-28 | -$52.18M derived: sum of 3 quarters · filed 2023-02-28 | -$60.33M 10-K · filed 2023-02-28 | ||
| 2020-09-30 | -$15.85M 10-Q · filed 2022-11-03 | -$16.69M 6-K · filed 2021-11-09 | -$33.38M derived: sum of 2 quarters · filed 2022-11-03 | -$41.53M 6-K · filed 2021-11-09 | ||
| 2020-06-30 | -$17.53M 10-Q · filed 2022-08-04 | -$16.25M 6-K · filed 2021-08-11 | -$24.83M 6-K · filed 2021-08-11 | |||
| 2020-03-31 | -$8.59M 6-K · filed 2021-11-09 | |||||
| 2019-12-31 | -$19.61M 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |